Ascierto, Paolo A.

Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort

Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., et al. (2020) · Journal of Thoracic Oncology

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 315

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Cited by 275

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 253

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., et al. (2005) · Journal of Clinical Oncology

Bacterial Cancer TherapyMelanoma and MAPK Pathways

Cited by 238

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 180

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 150

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 108

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 104

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment

Jänne, P. A., Bigot, F., Papadopoulos, K., Eberst, L., Sommerhalder, D., Lebellec, L., Voon, P. J., Pellini, B., Kalinka, E., Arbour, K., et al. (2023) · Molecular Cancer Therapeutics

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 63

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients

Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 40

Phenotype characterization of human melanoma cells resistant to dabrafenib

Cordaro, F. G., De Presbiteris, A. L., Camerlingo, R., Mozzillo, N., Pirozzi, G., Cavalcanti, E., Manca, A., Palmieri, G., Cossu, A., Ciliberto, G., et al. (2017) · Oncology Reports

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 38

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 30

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 14

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

Grimaldi, A., Simeone, E., Festino, L., Giannarelli, D., Palla, M., Caracò, C., Curvietto, M., Esposito, A., Grimaldi, M., Mozzillo, N., et al. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 11

Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

Grob, J.-J., Schadendorf, D., Wagstaff, J., Márquez-Rodas, I., Lebbé, C., Ascierto, P. A., Hodi, F. S., Grossmann, K., Hassel, J. C., Walker, D., et al. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 8

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Curvietto, M., Khoo, C., Atkinson, V., Lo, S., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2